Search - tctmd.com

Displaying 1 - 20 of 38

Sort: Relevancy | Date

Top General Cardiology and Prevention News of 2024

News Daily News

Top General Cardiology and Prevention News of 2024

December 30, 2024

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Topline Results

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

News Daily News

Increased CVD Risk Seen Up to 30 Years Before Type 2 Diabetes Diagnosis

November 28, 2024

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

News Daily News

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

November 27, 2024

November 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

November 26, 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

News Conference News AHA 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Michael O'Riordan

November 17, 2024

Presentation AHA 2024

Effect of Tirzepatide on Major Heart Failure Outcomes in Patients With Heart Failure With a Preserved Ejection Fraction and Obesity: The SUMMIT Trial

Presenter: Milton Packer

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

News Daily News

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

November 13, 2024

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

October 23, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows

News Daily News

Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows

September 25, 2024

More Data Diminish Support for Cath Lab Fasting Rules: SCOFF

News Conference News ESC 2024

More Data Diminish Support for Cath Lab Fasting Rules: SCOFF

September 10, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Stop-or-Not It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

News Conference News ESC 2024

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

August 30, 2024

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

August 05, 2024

Semaglutide May Ease Tobacco Use, Study Suggests

News Daily News

Semaglutide May Ease Tobacco Use, Study Suggests

August 01, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.